JP2012512634A5 - - Google Patents

Download PDF

Info

Publication number
JP2012512634A5
JP2012512634A5 JP2011541231A JP2011541231A JP2012512634A5 JP 2012512634 A5 JP2012512634 A5 JP 2012512634A5 JP 2011541231 A JP2011541231 A JP 2011541231A JP 2011541231 A JP2011541231 A JP 2011541231A JP 2012512634 A5 JP2012512634 A5 JP 2012512634A5
Authority
JP
Japan
Prior art keywords
synuclein
amino acid
seq
residues
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011541231A
Other languages
English (en)
Japanese (ja)
Other versions
JP5810413B2 (ja
JP2012512634A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/009186 external-priority patent/WO2010069603A1/en
Publication of JP2012512634A publication Critical patent/JP2012512634A/ja
Publication of JP2012512634A5 publication Critical patent/JP2012512634A5/ja
Application granted granted Critical
Publication of JP5810413B2 publication Critical patent/JP5810413B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011541231A 2008-12-19 2009-12-21 ヒト抗アルファシヌクレイン自己抗体 Expired - Fee Related JP5810413B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13925308P 2008-12-19 2008-12-19
EP08022188 2008-12-19
US61/139,253 2008-12-19
EP08022188.0 2008-12-19
PCT/EP2009/009186 WO2010069603A1 (en) 2008-12-19 2009-12-21 Human anti-alpha-synuclein autoantibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014169009A Division JP2014221835A (ja) 2008-12-19 2014-08-22 ヒト抗アルファシヌクレイン自己抗体

Publications (3)

Publication Number Publication Date
JP2012512634A JP2012512634A (ja) 2012-06-07
JP2012512634A5 true JP2012512634A5 (enExample) 2013-02-14
JP5810413B2 JP5810413B2 (ja) 2015-11-11

Family

ID=40636880

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011541231A Expired - Fee Related JP5810413B2 (ja) 2008-12-19 2009-12-21 ヒト抗アルファシヌクレイン自己抗体
JP2014169009A Withdrawn JP2014221835A (ja) 2008-12-19 2014-08-22 ヒト抗アルファシヌクレイン自己抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014169009A Withdrawn JP2014221835A (ja) 2008-12-19 2014-08-22 ヒト抗アルファシヌクレイン自己抗体

Country Status (25)

Country Link
US (4) US8940276B2 (enExample)
EP (3) EP3521309A1 (enExample)
JP (2) JP5810413B2 (enExample)
KR (1) KR101781228B1 (enExample)
CN (1) CN102317316B (enExample)
AU (1) AU2009328505B2 (enExample)
BR (1) BRPI0923157B1 (enExample)
CA (1) CA2746778C (enExample)
CY (2) CY1116584T1 (enExample)
DK (2) DK2370466T3 (enExample)
EA (1) EA030826B1 (enExample)
ES (1) ES2544569T3 (enExample)
HR (1) HRP20150831T1 (enExample)
HU (1) HUE025150T2 (enExample)
IL (1) IL213482A (enExample)
MX (1) MX2011006422A (enExample)
NZ (1) NZ593964A (enExample)
PH (1) PH12016500658B1 (enExample)
PL (2) PL2370466T3 (enExample)
PT (1) PT2370466E (enExample)
RS (1) RS54259B1 (enExample)
SG (1) SG172121A1 (enExample)
SI (2) SI2370466T1 (enExample)
SM (1) SMT201500186B (enExample)
WO (1) WO2010069603A1 (enExample)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
US20100312105A1 (en) * 2007-10-31 2010-12-09 Alseres Pharmaceuticals, Inc. Methods for diagnosing and monitoring treatment of lewy body dementia by assessing dopamine transporter level
JP5747414B2 (ja) 2008-04-29 2015-07-15 バイオアークティック ニューロサイエンス アーベー α−シヌクレイン関連疾患についての治療および診断方法における使用のための抗体およびワクチン
EP3521309A1 (en) 2008-12-19 2019-08-07 Biogen International Neuroscience GmbH Human anti-alpha-synuclein antibodies
AT508638B1 (de) * 2009-08-21 2011-08-15 Affiris Ag Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien
US9116157B2 (en) * 2010-11-05 2015-08-25 Brandeis University Ice-cleaved alpha-synuclein as a biomarker
MX357193B (es) * 2011-06-23 2018-06-29 Univ Zuerich Moleculas de union anti-alfa sinucleina.
EP3964524A1 (en) 2011-10-28 2022-03-09 Biogen International Neuroscience GmbH Tdp-43 specific binding molecules
HUE037811T2 (hu) 2011-10-28 2018-09-28 Prothena Biosciences Ltd Alfa-szinukleint felismerõ humanizált antitestek
US20140295465A1 (en) * 2011-11-02 2014-10-02 Biogen Idec International Neuroscience Gmbh USE OF AN ANTI-alpha-SYNUCLEIN ANTIBODY TO DIAGNOSE AN ELEVATED LEVEL OF alpha-SYNUCLEIN IN THE BRAIN
WO2013098420A1 (en) 2011-12-28 2013-07-04 Immunoqure Ag Method of isolating human antibodies
CN108517010A (zh) 2012-01-27 2018-09-11 普罗典娜生物科学有限公司 识别α-突触核蛋白的人源化抗体
KR20140018691A (ko) * 2012-08-03 2014-02-13 가천대학교 산학협력단 시누클레인병증의 진단 방법 및 이를 위한 진단 키트
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
EP2787349A1 (en) * 2013-04-03 2014-10-08 Affiris AG Method for detecting proteinopathy-specific antibodies in a biological sample
EP2787348A1 (en) 2013-04-03 2014-10-08 Affiris AG Method for detecting aSyn-specific antibodies in a biological sample
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
KR102384115B1 (ko) * 2013-10-24 2022-04-07 나노소믹스 인코포레이티드 알쯔하이머병 및 다른 신경퇴행성 장애에 대한 바이오마커 및 진단 방법
WO2015075011A1 (en) * 2013-11-21 2015-05-28 F. Hoffmann-La Roche Ag ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE
CA2944402A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
EA201790165A1 (ru) 2014-07-29 2017-07-31 Нейриммьюн Холдинг Аг Происходящие от человека антитела к гентингтину (htt) и их применение
JP2017536102A (ja) * 2014-10-16 2017-12-07 ジェネンテック, インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
EP3091087A1 (en) 2015-05-08 2016-11-09 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Method for in vitro diagnosis of synucleinopathies using alpha-synuclein gene transcripts
JP5908149B1 (ja) * 2015-06-30 2016-04-26 グリー株式会社 ゲームプログラム、ゲーム制御方法、およびゲームコンピュータ
GB201512203D0 (en) * 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
EP4063858A1 (en) 2016-03-14 2022-09-28 Biogen International Neuroscience GmbH Antibody-dependent cell-mediated phagocytosis assay for reliably measuring uptake of aggregated proteins
WO2017207739A1 (en) 2016-06-02 2017-12-07 Medimmune Limited Antibodies to alpha-synuclein and uses thereof
US20190330318A1 (en) 2016-07-25 2019-10-31 Biogen Ma Inc. Anti-hspa5 (grp78) antibodies and uses thereof
CA3035080A1 (en) 2016-09-27 2018-04-05 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules
CN106568969B (zh) * 2016-10-19 2017-09-26 首都医科大学 一种丝氨酸129位磷酸化alpha‑突触核蛋白聚集体的ELISA检测方法
US10889635B2 (en) 2016-11-15 2021-01-12 H. Lundbeck A/S Agents, uses and methods for the treatment of synucleinopathy
CA3036592A1 (en) * 2016-12-12 2018-06-21 The Michael J. Fox Foundation For Parkinson's Research Antibodies to human alpha-synuclein
BR112018016717A2 (pt) 2016-12-16 2018-12-26 H Lundbeck As agentes, usos e métodos
US20200031895A1 (en) 2016-12-16 2020-01-30 Biogen Ma Inc. Stabilized proteolytically activated growth differentiation factor 11
KR102014066B1 (ko) 2017-01-06 2019-10-21 에이비엘바이오 주식회사 항 α-syn 항체 및 그 용도
EP3567054A4 (en) * 2017-01-06 2021-03-10 ABL Bio Inc. ANTI-ALPHA SYN ANTIBODIES AND USES THEREOF
BR112019016374A2 (pt) * 2017-02-17 2020-04-07 Bristol-Myers Squibb Company anticorpos para alfa-sinucleína e usos dos mesmos
JOP20190227A1 (ar) * 2017-03-31 2019-09-30 Biogen Int Neuroscience Gmbh تركيبات وطرق لعلاج اعتلالات السينوكلين
KR101896182B1 (ko) 2017-06-15 2018-09-07 재단법인대구경북과학기술원 알파-시누클레인 응집체 매개 세포독성을 억제하는 방법
AU2018283510B8 (en) * 2017-06-16 2025-09-18 United Neuroscience Peptide immunogens from the C-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies
US11098108B2 (en) 2017-08-02 2021-08-24 Stressmarq Biosciences Inc. Antibody binding active alpha-synuclein
EP4233901A3 (en) 2017-08-22 2023-09-06 Biogen MA Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
JP7286658B2 (ja) 2017-09-26 2023-06-05 セロ・セラピューティクス・インコーポレイテッド キメラエンガルフメント受容体分子および使用方法
JP2021502955A (ja) 2017-09-28 2021-02-04 プロセナ・バイオサイエンシズ・リミテッド シヌクレイン病の治療のための投与レジメン
AU2018370279B2 (en) * 2017-11-17 2022-11-03 Abl Bio Inc. Antibodies to a-synuclein and uses thereof
BR112020011875A2 (pt) 2017-12-14 2020-11-24 Abl Bio Inc. anticorpo biespecífico ao a-syn/igf1r e uso do mesmo
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
EP3728317A2 (en) 2017-12-21 2020-10-28 F. Hoffmann-La Roche AG Antibodies binding to hla-a2/wt1
MX2020007433A (es) * 2018-01-12 2020-09-14 Bristol Myers Squibb Co Oligonucleotidos antisentido que actuan sobre alfa-sinucleina, y usos de estos.
EA202091693A1 (ru) 2018-01-12 2021-04-14 Бристол-Маерс Сквибб Компани Антисмысловые олигонуклеотиды, целенаправленно воздействующие на альфа-синуклеин, и их применения
WO2019191332A1 (en) 2018-03-28 2019-10-03 Cero Therapeutics, Inc. Chimeric engulfment receptors and uses thereof for neurodegenerative diseases
AU2019243154A1 (en) 2018-03-28 2020-10-01 Cero Therapeutics, Inc. Cellular immunotherapy compositions and uses thereof
WO2020003203A1 (en) * 2018-06-27 2020-01-02 Mor Research Applications Antibodies for the treatment of synucleinopathies and neuroinflammation
WO2020009482A1 (ko) * 2018-07-03 2020-01-09 에이비엘바이오 주식회사 항 알파-시누클레인 항체 및 그 용도
AU2019318195A1 (en) 2018-08-09 2021-03-04 F. Hoffmann-La Roche Ag Determination of parkinson's disease
KR20210111242A (ko) 2018-10-29 2021-09-10 바이오젠 엠에이 인코포레이티드 혈액 뇌 장벽 수송을 향상시키기 위한 인간화 및 안정화된 fc5 변이체
CA3118692A1 (en) * 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
US11542322B2 (en) 2019-02-13 2023-01-03 Iowa State University Research Foundation, Inc. Nano-theranostics for Parkinson's disease
CN114341343B (zh) * 2019-04-30 2024-11-15 才思治疗公司 α-突触核蛋白测定
KR102143189B1 (ko) * 2019-05-08 2020-08-11 주식회사 피플바이오 파킨슨병의 진단 방법 및 이를 위한 진단 키트
CA3159964A1 (en) * 2019-12-04 2021-06-10 Ac Immune Sa Novel molecules for therapy and diagnosis
NL2025332B1 (en) * 2020-04-10 2021-10-26 Syngle Therapeutics B V Novel alpha-synuclein binding antibodies, or antigen binding portions thereof.
CN115427443A (zh) 2020-04-24 2022-12-02 豪夫迈·罗氏有限公司 巯基化合物及其衍生物的酶和途径调节
MX2022014319A (es) * 2020-05-18 2023-02-27 Amprion Inc Sustratos de alfa-sinucleína y métodos para la fabricación y el uso de los mismos.
MD4172199T2 (ro) * 2020-06-26 2025-09-30 Bioarctic Ab Anticorpi care leagă protofibrila de alfa-sinucleină
JP2023541048A (ja) 2020-09-10 2023-09-27 プロシーナ バイオサイエンシーズ リミテッド パーキンソン病の処置
CN112920274A (zh) * 2021-03-17 2021-06-08 江苏贝格尔生物医药有限公司 一种检测alpha-synuclein蛋白的鼠单克隆抗体及其应用
CA3239708A1 (en) 2021-12-03 2023-06-08 Aubin MICHALON Novel potency assay for antibody-based drugs and useful means therefor
CN117645665B (zh) * 2024-01-29 2024-05-07 北京热景生物技术股份有限公司 一种针对α-突触核蛋白的抗体及其制备方法和应用
WO2025245381A1 (en) 2024-05-23 2025-11-27 The Trustrees Of Dartmouth College Methods and compositions for enhancing the persistence of car expressing tregs in the cns and other tissues
CN119751671B (zh) * 2025-01-17 2025-07-11 首都医科大学宣武医院 一种特异性结合α-突触核蛋白的抗体及其相关产品和用途

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
JPH02503867A (ja) 1988-04-15 1990-11-15 プロテイン デザイン ラブズ インコーポレーテッド Il‐2レセプター特異的キメラ抗体
EP0428534B1 (en) 1988-06-14 1995-03-29 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
EP0521985B1 (en) 1990-03-20 1997-09-24 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
ES2178635T3 (es) 1990-11-09 2003-01-01 Stephen D Gillies Inmunoconjugados de citoquinas.
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
JPH07509137A (ja) 1992-07-24 1995-10-12 セル ジェネシス,インク. 異種抗体の生産
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
DE669986T1 (de) 1992-11-13 1996-10-10 Idec Pharma Corp Völlig unfunktionelle konsensus-kozak-sequenzen zur säugetier-exprimierung.
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5676950A (en) 1994-10-28 1997-10-14 University Of Florida Enterically administered recombinant poxvirus vaccines
ATE213499T1 (de) 1994-11-18 2002-03-15 Neurocrine Biosciences Inc Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
PL191251B1 (pl) 1997-03-14 2006-04-28 Idec Pharma Corp Sposób wprowadzania żądanego DNA w docelowe miejsce w genomie ssaka i układ wektorów
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US20020086847A1 (en) 1997-04-09 2002-07-04 Mindset Biopharmaceuticals (Usa) Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
CN1177616C (zh) 1997-04-09 2004-12-01 曼德塞特生物制药公司 特异于β-淀粉状蛋白末端的重组抗体,编码它们的DNA及其使用方法
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
US6703015B1 (en) 1999-09-03 2004-03-09 Ramot At Tel-Aviv University Ltd. Filamentous bacteriophage displaying an β-amyloid epitope
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
WO1999050300A1 (en) 1998-03-30 1999-10-07 The Trustees Of The University Of Pennsylvania Method of identifying, diagnosing and treating synuclein positive neurodegenerative disorders
AU1631700A (en) 1998-11-23 2000-06-13 Idec Pharmaceuticals Corporation Tumor antigen-specific antibody-gp39 chimeric protein constructs
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
CA2274414A1 (en) 1999-06-11 2000-12-11 Universite Laval Dietary fish protein for use in restoring normal insulin function insulin-resistant individuals
US6919075B1 (en) 1999-09-03 2005-07-19 Ramot At Tel Aviv University Ltd. Bacteriophage displaying aβ epitopes and method of use
US6294171B2 (en) 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
US6436401B1 (en) 1999-09-14 2002-08-20 Milkhaus Laboratory, Inc. Methods for alleviating symptoms associated with diabetes and diabetic neuropathy comprising administration of low levels of antibodies
US6187309B1 (en) 1999-09-14 2001-02-13 Milkaus Laboratory, Inc. Method for treatment of symptoms of central nervous system disorders
US6713058B2 (en) 1999-09-14 2004-03-30 Milkhaus Laboratory, Inc. Methods for alleviating symptoms associated with neuropathic conditions comprising administration of low levels of antibodies
KR100823764B1 (ko) 2000-06-22 2008-04-21 제넨테크, 인크. 아고니스트 안티-티알케이-씨 모노클로날 항체
AU2001268005A1 (en) 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
JP4368196B2 (ja) 2000-11-17 2009-11-18 ユニバーシティー オブ ロチェスター 真核細胞において免疫グロブリン分子を製造および同定するインビトロにおける方法
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
EP1373321A2 (en) 2001-01-29 2004-01-02 Idec Pharmaceuticals Corporation Modified antibodies and methods of use
ITPV20010007U1 (it) 2001-07-19 2003-01-19 Maruscia Food Specialties Comp Contenitore per profilattico nuovo e usato
ES2391905T3 (es) 2001-08-17 2012-11-30 Washington University Método de ensayo para la enfermedad de alzheimer
US7414111B2 (en) 2001-09-19 2008-08-19 Alexion Pharmaceuticals, Inc. Engineered templates and their use in single primer amplification
US20030157641A1 (en) 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
GB0203446D0 (en) 2002-02-14 2002-04-03 Univ Lancaster Detection and/or monitoring of synuclein-related diseases
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US20110200609A1 (en) 2002-09-12 2011-08-18 The Regents Of The University Of California Monoclonal antibodies specific for pathological amyloid aggregates common to amyloids formed from proteins of differing sequence
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
EP1571211B1 (en) 2002-11-22 2010-01-20 Chugai Seiyaku Kabushiki Kaisha Antibodies against lesional tissues
US20060240485A1 (en) 2003-04-24 2006-10-26 Universitat Zurich Method of monitoring immunotherapy
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
WO2005018424A2 (en) 2003-08-18 2005-03-03 Research Foundation For Mental Hygiene, Inc. Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
NZ545776A (en) 2003-08-22 2009-05-31 Biogen Idec Inc Improved antibodies having altered effector function and methods for making the same
US20070031416A1 (en) 2003-09-09 2007-02-08 Takeda Pharmaceutical Company Limited Use of antibody
US7674599B2 (en) 2003-11-08 2010-03-09 Elan Pharmaceuticals, Inc. Methods of using antibodies to detect alpha-synuclein in fluid samples
AU2005217596B2 (en) 2004-02-23 2012-01-19 Eli Lilly And Company Anti-ABeta antibody
JPWO2005105998A1 (ja) 2004-04-27 2008-07-31 財団法人化学及血清療法研究所 ヒト抗アミロイドβペプチド抗体およびその抗体フラグメント
DE602005022871D1 (de) 2004-06-07 2010-09-23 Univ Ramot Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
MX2007001679A (es) 2004-08-09 2007-05-23 Elan Pharm Inc Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
WO2006050041A2 (en) 2004-10-28 2006-05-11 Ramot At Tel Aviv University Ltd. Methods for reducing or inhibiting brain inflammation or for promoting neurogenesis
US7625560B2 (en) 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
EP1838349A1 (en) 2004-12-15 2007-10-03 Neuralab, Ltd. Amyloid beta antibodies for use in improving cognition
ATE458754T1 (de) 2005-03-05 2010-03-15 Abbott Gmbh & Co Kg Screening-verfahren, verfahren zur aufreinigung nichtdiffundierbarer a-beta-oligomere, selektive antikörper gegen diese nichtdiffundierbaren a- beta-oligomere und verfahren zur herstellung dieser antikörper
JP2006265189A (ja) 2005-03-24 2006-10-05 Kyoto Univ βアミロイドペプチド、及びそれを用いたアルツハイマー病治療薬又は予防薬のスクリーニング方法
ES2318918B1 (es) 2005-04-01 2010-02-16 Biotherapix Molecular Medicines, S.L.U. Anticuerpos humanos con capacidad de union al peptido beta-amiloide y sus aplicaciones.
WO2006116192A2 (en) 2005-04-21 2006-11-02 Medarex, Inc. Irta-1 antibodies and their uses
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
US20080300204A1 (en) 2005-07-19 2008-12-04 University Of Rochester Alpha-Synuclein Antibodies and Methods Related Thereto
WO2007021255A1 (en) 2005-08-09 2007-02-22 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
JP2009521403A (ja) 2005-11-14 2009-06-04 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク Mriによる神経発生の相関の画像法
US9133267B2 (en) 2005-11-22 2015-09-15 The Trustees Of The University Of Pennsylvania Antibody treatment of Alzheimer's and related diseases
KR20180058863A (ko) 2005-11-30 2018-06-01 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
MX2008006957A (es) 2005-11-30 2008-10-20 Abbott Lab Metodos para la preparacion de formas recombinantes de proteina beta-amiloide humana y usos de estas proteinas.
PT1954718E (pt) 2005-11-30 2014-12-16 Abbvie Inc Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
CA2632822C (en) 2005-12-12 2018-08-28 Ruth Greferath A beta 1-42 specific monoclonal antibodies with therapeutic properties
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2099826B1 (en) 2007-01-05 2013-10-16 University Of Zurich Anti-beta-amyloid antibody and uses thereof
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
JP5558834B2 (ja) 2007-02-23 2014-07-23 ヤンセン アルツハイマー イミュノセラピー シヌクレイノパチーおよびアミロイド形成疾患(amyloidogenicdisease)の予防および処置
MX2009009926A (es) 2007-03-13 2010-03-15 Univ Zuerich Anticuerpo tumor-especifico humano monoclonal.
EP2146746A4 (en) 2007-04-18 2011-03-23 Janssen Alzheimer Immunotherap PREVENTIVE AND TREATING ZEREBRALER AMYLOID ANGIOPATHY
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
CN101778867A (zh) 2007-06-08 2010-07-14 地中海大学 用于治疗胰腺肿瘤的组合物和方法
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
US9370531B2 (en) 2007-08-31 2016-06-21 New York University Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
WO2009033743A1 (en) 2007-09-13 2009-03-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
SI2207809T1 (sl) 2007-09-26 2013-11-29 U3 Pharma Gmbh Proteini, ki veĹľejo antigen rastnega faktorja, podobnega epidermalnemu rastnemu faktorju, ki veĹľe heparin
EP2210901A4 (en) 2007-10-19 2012-04-25 Immunas Pharma Inc FOR THE SPECIFIC BINDING TO AN OLIGOMICALLY ABLE ANTIBODY AND ITS USE
GB0720912D0 (en) 2007-10-25 2007-12-05 Univ Cardiff Monoclonal Anitbody for APP
US8343493B2 (en) 2007-10-29 2013-01-01 Innogenetics N.V. Antibodies specific of the β-amyloid peptides and their uses as diagnostic agents or drugs
US8470321B2 (en) 2007-11-16 2013-06-25 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
EP2261254A3 (en) 2007-12-21 2011-04-13 Amgen, Inc Anti-amyloid antibodies and uses thereof
AT506535B1 (de) 2008-02-22 2010-04-15 Affiris Forschungs & Entwicklungs Gmbh Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
JP5747414B2 (ja) 2008-04-29 2015-07-15 バイオアークティック ニューロサイエンス アーベー α−シヌクレイン関連疾患についての治療および診断方法における使用のための抗体およびワクチン
US20110182809A1 (en) 2008-07-09 2011-07-28 University Of Zurich Method of Promoting Neurogenesis
EP2344541A2 (en) 2008-09-19 2011-07-20 MedImmune, LLC Antibodies directed to cd105 and uses thereof
EP2365804B1 (en) 2008-11-13 2015-05-06 Modgene, Llc Reduction of amyloid-beta load in non-brain tissue
EP3521309A1 (en) 2008-12-19 2019-08-07 Biogen International Neuroscience GmbH Human anti-alpha-synuclein antibodies
US20100256596A1 (en) 2009-04-07 2010-10-07 Cabochon Aesthetics, Inc. Fiber growth promoting implants for reducing the appearance of cellulite
WO2010119704A1 (en) 2009-04-17 2010-10-21 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
US8613924B2 (en) 2009-08-06 2013-12-24 Immunas Pharma, Inc. Antibodies that specifically bind to A beta oligomers and use thereof
ES2624835T3 (es) 2009-08-06 2017-07-17 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos
IN2012DN01776A (enExample) 2009-09-02 2015-06-05 Du Pont
MX357193B (es) 2011-06-23 2018-06-29 Univ Zuerich Moleculas de union anti-alfa sinucleina.
US20140295465A1 (en) 2011-11-02 2014-10-02 Biogen Idec International Neuroscience Gmbh USE OF AN ANTI-alpha-SYNUCLEIN ANTIBODY TO DIAGNOSE AN ELEVATED LEVEL OF alpha-SYNUCLEIN IN THE BRAIN
ITRM20120383A1 (it) 2012-03-20 2013-09-21 Uni Degli Studi Di Milano B Icocca Metodo e kit per la rivelazione di anticorpi.
JOP20190227A1 (ar) 2017-03-31 2019-09-30 Biogen Int Neuroscience Gmbh تركيبات وطرق لعلاج اعتلالات السينوكلين

Similar Documents

Publication Publication Date Title
JP2012512634A5 (enExample)
CA2861793C (en) Method of providing monoclonal auto-antibodies with desired specificity
CA2939293C (en) Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
JP7046804B2 (ja) 改良された血清アルブミン結合剤
KR102014554B1 (ko) Fc 수용체 결합 단백질
US9783589B2 (en) Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases
JP2014528695A5 (enExample)
EP2185592B1 (en) Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
JP2012518425A5 (enExample)
US20200031934A1 (en) B7-h3 antibody, antigen-binding fragment thereof and medical use thereof
HRP20150831T1 (hr) Humana anti-alfa- sinuklein auto-protutijela
US10875916B2 (en) Nucleic acid molecules encoding monoclonal antibodies specific for IL-17F
JP6908709B2 (ja) 抗α−syn抗体およびその使用
JP2015505665A5 (enExample)
JP2018166506A5 (enExample)
JP2008529489A5 (enExample)
JP2014503178A5 (enExample)
IL261666B2 (en) Binding proteins and methods of use thereof
WO2014025828A1 (en) Engineered antibody fragments for targeting and imaging cd8 expression in vivo
JP2009517057A5 (enExample)
JP2014533357A5 (enExample)
CA2894178A1 (en) A method of reducing brain amyloid plaques using anti-a.beta. antibodies
WO2019137397A1 (zh) Pd-l1抗体、其抗原结合片段及医药用途
JP2015506945A5 (enExample)
TWI801425B (zh) Il-5 抗體、其抗原結合片段及醫藥用途